CRBP Corbus Pharmaceuticals
- 43.7750
- -2.1450-4.67%
Corbus Pharmaceuticals News
Cannabis Stock Gainers And Losers From May 16, 2024
GAINERS:Flower One Hldgs (OTC:FLOOF) shares closed up 900.00% at $1e-05Cannabix Technologies (OTC:BLOZF) shares closed up 28.41% at $0.60Greenlane Hldgs (NASDAQ:GNLN) shares closed up 16.06% at $0.61C
Attention Biotech Investors - Stocks To Watch
At the RBC Global Healthcare Conference, held on 14-15 May, RBC's Healthcare Desk Sector Strategist gauged biotech investor sentiment in an interview with Biotech TV.The strategist, Chris McCarthy, sa
Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028. This growth would be primarily fueled by the expansion of ad
Corbus Pharmaceuticals Initiated at Outperform by RBC Capital
Corbus Pharmaceuticals Initiated at Outperform by RBC Capital
Corbus Pharmaceuticals (CRBP.US) was first covered by the Royal Bank of Canada, which gave it an superior market rating, with a target price of $77.00.
Corbus Pharmaceuticals (CRBP.US) was first covered by the Royal Bank of Canada, which gave it an superior market rating, with a target price of $77.00.
RBC Capital Initiates Coverage On Corbus Pharmaceuticals With Outperform Rating, Announces Price Target of $77
RBC Capital analyst Brian Abrahams initiates coverage on Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform rating and announces Price Target of $77.
Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) Largest Shareholders Are Individual Investors Who Were Rewarded as Market Cap Surged US$58m Last Week
Key Insights Significant control over Corbus Pharmaceuticals Holdings by individual investors implies that the general public has more power to influence management and governance-related decisions
Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
NORWOOD, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of
Cannabis Stock Movers For May 8, 2024
GAINERS:Khiron Life Sciences (OTC:KHRNF) shares closed up 9900.00% at $0.0001Affinor Growers (OTC:RSSFF) shares closed up 18.15% at $0.08Eastside Distilling (NASDAQ:EAST) shares closed up 16.81% at $1
Form 144 | Corbus Pharmaceuticals(CRBP.US) Insider Proposes to Sell 634.88K in Common Stocks
SEC FILLINGS DISCLOSED/ May 8, $Corbus Pharmaceuticals(CRBP.US)$ Insider Brake Rachael Louise intends to sell 15,550 shares of its common stock on May 8, with a total market value of approximately $63
Corbus Pharmaceuticals Currently Up Nine Consecutive Days, on Track for Record Winning Streak -- Data Talk
Corbus Pharmaceuticals Holdings Inc (CRBP) is currently at $40.78, up $1.01 or 2.55% --Would be highest close since April 16, 2024, when it closed at $41.12 --Currently up nine consecutive days; up
Corbus Pharmaceuticals Is Maintained at Outperform by Oppenheimer
Corbus Pharmaceuticals Is Maintained at Outperform by Oppenheimer
Corbus Pharmaceuticals Price Target Raised to $60.00/Share From $58.00 by Oppenheimer
Corbus Pharmaceuticals Price Target Raised to $60.00/Share From $58.00 by Oppenheimer
Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Raises Price Target to $60
Oppenheimer analyst Jeff Jones maintains Corbus Pharmaceuticals with a Outperform and raises the price target from $58 to $60.
Corbus Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/08/2024 36.36% Oppenheimer $58 → $60 Maintains Outperform 03/13/2024 31.82% Oppenheimer $51 → $58 Reite
Corbus Pharmaceuticals | 10-Q: Quarterly report
Corbus Pharmaceuticals Financial Performance Update Insights
Corbus Pharmaceuticals 1Q Loss/Shr 83c >CRBP
Corbus Pharmaceuticals 1Q Loss/Shr 83c >CRBP
Press Release: Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
NORWOOD, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company with a diversified portfolio, today provided a corporate update and reported financial results for the quarter ended March 31, 2024.
Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum
NORWOOD, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of
Analysis
Price Target
No Data
